Skip to content
Biodatica
Start free

Genentech, Inc.

Duarte, California

OncologyFiled/ApprovedListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase II trial registered: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

5d agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)

Momentum

98no change

Momentum 98 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jun 5, 2026

    Atherosclerosis · RECRUITING · sponsor: Genentech, Inc. · A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

    ClinicalTrials.gov · NCT07448038 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Oct 7, 2025

    Breast Cancer · RECRUITING · sponsor: Genentech, Inc. · A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    ClinicalTrials.gov · NCT07100106 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 8, 2024

    Colorectal Cancer, Non-Small Cell Lung Cancer · COMPLETED · sponsor: Genentech, Inc. · Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

    ClinicalTrials.gov · NCT05954871 (opens the source filing in a new tab)

  4. Trial

    PHASE4 registered

    Jul 30, 2020

    Multiple Sclerosis, Relapsing · COMPLETED · sponsor: Genentech, Inc. · Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

    ClinicalTrials.gov · NCT04377555 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Nov 24, 2017

    Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Genentech, Inc. · A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

    ClinicalTrials.gov · NCT03332797 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Dec 13, 2016

    Breast Cancer, Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Genentech, Inc. · To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

    ClinicalTrials.gov · NCT03006172 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources